Pharmaceutical CDMO Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pharmaceutical CDMO Market 

5.1. COVID-19 Landscape: Pharmaceutical CDMO Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pharmaceutical CDMO Market, By Product

8.1. Pharmaceutical CDMO Market, by Product, 2024-2033

8.1.1. API

8.1.1.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Pharmaceutical CDMO Market, By Drug Product

9.1. Pharmaceutical CDMO Market, by Drug Product, 2024-2033

9.1.1. Oral Solid Dose

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Semi-solid dose

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Liquid Dose

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Pharmaceutical CDMO Market, By Dosage Form 

10.1. Pharmaceutical CDMO Market, by Dosage Form, 2024-2033

10.1.1. Solid

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Semi-Solid

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Liquid Dose Formulation

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Gas Dose Formulation

10.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Pharmaceutical CDMO Market, By Indication

11.1. Pharmaceutical CDMO Market, by Indication, 2024-2033

11.1.1. Cancer

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Cardiovascular Disease

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Diabetes

11.1.3.1. Market Revenue and Forecast (2021-2033)

11.1.4. Pain

11.1.4.1. Market Revenue and Forecast (2021-2033)

11.1.5. Respiratory disease

11.1.5.1. Market Revenue and Forecast (2021-2033)

11.1.6. Other Disease

11.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Pharmaceutical CDMO Market, By End-User

12.1. Pharmaceutical CDMO Market, by End-User, 2024-2033

12.1.1. Big Pharmaceutical Companies

12.1.1.1. Market Revenue and Forecast (2021-2033)

12.1.2. Small & Medium-Sized Pharmaceutical Companies

12.1.2.1. Market Revenue and Forecast (2021-2033)

12.1.3. Generic Pharmaceutical Companies

12.1.3.1. Market Revenue and Forecast (2021-2033)

12.1.4. Other End Users

12.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 13. Global Pharmaceutical CDMO Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Product (2021-2033)

13.1.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.1.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.1.4. Market Revenue and Forecast, by Indication (2021-2033)

13.1.5. Market Revenue and Forecast, by End-User (2021-2033)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Product (2021-2033)

13.1.6.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.1.6.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.1.6.4. Market Revenue and Forecast, by Indication (2021-2033)

13.1.6.5. Market Revenue and Forecast, by End-User (2021-2033) 

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Product (2021-2033)

13.1.7.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.1.7.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.1.7.4. Market Revenue and Forecast, by Indication (2021-2033)

13.1.7.5. Market Revenue and Forecast, by End-User (2021-2033)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Product (2021-2033)

13.2.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.2.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.2.4. Market Revenue and Forecast, by Indication (2021-2033) 

13.2.5. Market Revenue and Forecast, by End-User (2021-2033) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Product (2021-2033)

13.2.6.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.2.6.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.2.7. Market Revenue and Forecast, by Indication (2021-2033) 

13.2.8. Market Revenue and Forecast, by End-User (2021-2033) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Product (2021-2033)

13.2.9.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.2.9.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.2.10. Market Revenue and Forecast, by Indication (2021-2033)

13.2.11. Market Revenue and Forecast, by End-User (2021-2033)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Product (2021-2033)

13.2.12.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.2.12.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.2.12.4. Market Revenue and Forecast, by Indication (2021-2033)

13.2.13. Market Revenue and Forecast, by End-User (2021-2033)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Product (2021-2033)

13.2.14.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.2.14.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.2.14.4. Market Revenue and Forecast, by Indication (2021-2033)

13.2.15. Market Revenue and Forecast, by End-User (2021-2033)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Product (2021-2033)

13.3.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.3.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.3.4. Market Revenue and Forecast, by Indication (2021-2033)

13.3.5. Market Revenue and Forecast, by End-User (2021-2033)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Product (2021-2033)

13.3.6.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.3.6.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.3.6.4. Market Revenue and Forecast, by Indication (2021-2033)

13.3.7. Market Revenue and Forecast, by End-User (2021-2033)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Product (2021-2033)

13.3.8.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.3.8.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.3.8.4. Market Revenue and Forecast, by Indication (2021-2033)

13.3.9. Market Revenue and Forecast, by End-User (2021-2033)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Product (2021-2033)

13.3.10.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.3.10.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.3.10.4. Market Revenue and Forecast, by Indication (2021-2033)

13.3.10.5. Market Revenue and Forecast, by End-User (2021-2033)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Product (2021-2033)

13.3.11.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.3.11.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.3.11.4. Market Revenue and Forecast, by Indication (2021-2033)

13.3.11.5. Market Revenue and Forecast, by End-User (2021-2033)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Product (2021-2033)

13.4.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.4.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.4.4. Market Revenue and Forecast, by Indication (2021-2033)

13.4.5. Market Revenue and Forecast, by End-User (2021-2033)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Product (2021-2033)

13.4.6.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.4.6.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.4.6.4. Market Revenue and Forecast, by Indication (2021-2033)

13.4.7. Market Revenue and Forecast, by End-User (2021-2033)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Product (2021-2033)

13.4.8.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.4.8.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.4.8.4. Market Revenue and Forecast, by Indication (2021-2033)

13.4.9. Market Revenue and Forecast, by End-User (2021-2033)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Product (2021-2033)

13.4.10.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.4.10.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.4.10.4. Market Revenue and Forecast, by Indication (2021-2033)

13.4.10.5. Market Revenue and Forecast, by End-User (2021-2033)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Product (2021-2033)

13.4.11.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.4.11.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.4.11.4. Market Revenue and Forecast, by Indication (2021-2033)

13.4.11.5. Market Revenue and Forecast, by End-User (2021-2033)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Product (2021-2033)

13.5.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.5.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.5.4. Market Revenue and Forecast, by Indication (2021-2033)

13.5.5. Market Revenue and Forecast, by End-User (2021-2033)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Product (2021-2033)

13.5.6.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.5.6.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.5.6.4. Market Revenue and Forecast, by Indication (2021-2033)

13.5.7. Market Revenue and Forecast, by End-User (2021-2033)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Product (2021-2033)

13.5.8.2. Market Revenue and Forecast, by Drug Product (2021-2033)

13.5.8.3. Market Revenue and Forecast, by Dosage Form (2021-2033)

13.5.8.4. Market Revenue and Forecast, by Indication (2021-2033)

13.5.8.5. Market Revenue and Forecast, by End-User (2021-2033)

Chapter 14. Company Profiles

14.1. Bushu Pharmaceuticals Ltd.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Nipro Corporation

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Thermo Fisher Scientific Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Samsung Biologics

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Laboratory Corporation of America Holdings

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Siegfried Holding Ag

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Catalent, Inc

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Lonza Group AG

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Recipharm Ab

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Piramal Pharma Solutions

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms